Menu

Mass Resignation from Scientific Reports’s Editorial Board

Nineteen researchers have stepped down after the journal decided not to retract a paper that they say plagiarized the work of a Johns Hopkins biomedical scientist.

Nov 6, 2017
Catherine Offord

ISTOCK, SPRNG23Update (March 20): Scientific Reports retracted the 2016 study today. It has been cited 17 times since its publication. In a statement to Retraction Watch, the journal acknowledged that “the correction made following the initial review was insufficient and inadequate,” and noted that editorial staff would receive further guidance on “handling allegations of plagiarism.”

Nearly 20 researchers, most of whom are based at Johns Hopkins University, have resigned from the editorial board of Scientific Reports following a dispute about an allegedly plagiarized study published by the journal in 2016, Retraction Watch reports today (November 7). The resignations follow months of back-and-forth between the journal and members of its editorial board, culminating in an email sent yesterday by managing editor Richard White notifying the researchers that “we do not think retraction is warranted” for the disputed study.

“I resigned as soon as I learned that Scientific Reports elected not to retract the paper,” Ted Dawson, a Johns Hopkins neurobiologist, writes in an email to Retraction Watch. “It seems Scientific Reports has a unique publication policy—‘If you are caught plagiarizing someone else’s work in Scientific Reports, all you need to do is apologize and publish a corrigendum.’  I don’t think this is something the community should support or we are condoning this behavior.”

The study in question—a paper authored by a research group in China that describes a method to identify regulatory DNA sequences—came under fire shortly after it was published. Johns Hopkins biomedical scientist Michael Beer claimed that the authors had plagiarized his work, essentially copying large sections of a paper his group published in PLOS Computational Biology in 2014.

The dispute escalated when White declined to retract the paper in late 2016, writing to Beer that although the authors’ claims to novelty were “overstated . . . the inaccuracies and ambiguities in the paper do not warrant its retraction, but we will publish a corrigendum.” The journal has posted a correction to provide more credit to other Beer and his colleagues.

Since then, Retraction Watch reported earlier this year, researchers from Johns Hopkins have been resigning in protest from the journal’s editorial board, which numbers in the thousands of researchers.

The latest wave of resignations is part of a response coordinated by Hopkins researcher Steven Salzberg, who became involved after hearing about the issue from Beer. As of today, 19 researchers—17 from Johns Hopkins—have now stepped down.

“We are very disappointed by [the journal’s] decision,” wrote Salzberg in an email sent to White, cosigned by other researchers invested in the dispute. “You have decided to reward plagiarism by allowing the authors to make a few minor revisions, and keep their paper in the literature. When a student plagiarizes, we don’t give him a chance to revise and resubmit: we give him a failing grade and sometimes take even stronger disciplinary action, up to and including expulsion. Your journal is thus setting a very poor example.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.